1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one
| Title | Journal |
|---|---|
| Cytotoxicity of 34 FDA approved small-molecule kinase inhibitors in primary rat and human hepatocytes. | Toxicology letters 20180701 |
| Promising efficacy of novel BTK inhibitor AC0010 in mantle cell lymphoma. | Journal of cancer research and clinical oncology 20180401 |
| Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL). | Expert opinion on investigational drugs 20180101 |
| The Phospholipase Cγ2 Mutants R665W and L845F Identified in Ibrutinib-resistant Chronic Lymphocytic Leukemia Patients Are Hypersensitive to the Rho GTPase Rac2 Protein. | The Journal of biological chemistry 20161014 |
| Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma. | Oncotarget 20160906 |
| Mantle Cell Lymphoma. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20160410 |
| Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. | The New England journal of medicine 20160128 |
| Label-Free Bottom-Up Proteomic Workflow for Simultaneously Assessing the Target Specificity of Covalent Drug Candidates and Their Off-Target Reactivity to Selected Proteins. | Chemical research in toxicology 20160119 |
| Dual inhibition of CDK4/Rb and PI3K/AKT/mTOR pathways by ON123300 induces synthetic lethality in mantle cell lymphomas. | Leukemia 20160101 |
| Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib. | Blood 20150924 |
| Ibrutinib: a review of its use in patients with mantle cell lymphoma or chronic lymphocytic leukaemia. | Drugs 20150501 |
| Ibrutinib in pretreated Waldenström's macroglobulinaemia. | The Lancet. Oncology 20150501 |
| Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors. | Leukemia 20150401 |
| Absorption, metabolism, and excretion of oral ¹⁴C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men. | Drug metabolism and disposition: the biological fate of chemicals 20150201 |
| Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors. | Proceedings of the National Academy of Sciences of the United States of America 20140805 |
| Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity. | Journal of medicinal chemistry 20140626 |
| Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765). | Leukemia & lymphoma 20131101 |
| Ibrutinib: a novel Bruton's tyrosine kinase inhibitor with outstanding responses in patients with chronic lymphocytic leukemia. | Leukemia & lymphoma 20130801 |
| Identification of potent Yes1 kinase inhibitors using a library screening approach. | Bioorganic & medicinal chemistry letters 20130801 |
| Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. | The New England journal of medicine 20130704 |
| Ibrutinib: a strong candidate for the future of mantle cell lymphoma treatment. | Expert review of clinical immunology 20130601 |
| Ibrutinib (PCI-32765), the first BTK (Bruton's tyrosine kinase) inhibitor in clinical trials. | Current hematologic malignancy reports 20130301 |
| Ibrutinib and novel BTK inhibitors in clinical development. | Journal of hematology & oncology 20130101 |
| Inhibitors of B-cell receptor signaling for patients with B-cell malignancies. | Cancer journal (Sudbury, Mass.) 20120901 |
| Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. | Blood 20120830 |
| Irreversible protein kinase inhibitors: balancing the benefits and risks. | Journal of medicinal chemistry 20120726 |
| Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. | Cancer cell 20120612 |
| Bruton's tyrosine kinase inhibitors: approaches to potent and selective inhibition, preclinical and clinical evaluation for inflammatory diseases and B cell malignancies. | Journal of medicinal chemistry 20120524 |
| The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. | Blood 20120315 |
| Inhibiting B-cell receptor signaling pathways in chronic lymphocytic leukemia. | Current hematologic malignancy reports 20120301 |
| Novel targeted therapies for mantle cell lymphoma. | Oncotarget 20120201 |
| Imidazo[1,5-a]quinoxalines as irreversible BTK inhibitors for the treatment of rheumatoid arthritis. | Bioorganic & medicinal chemistry letters 20111101 |
| Modeling pharmacological inhibition of mast cell degranulation as a therapy for insulinoma. | Neoplasia (New York, N.Y.) 20111101 |
| Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. | Blood 20110609 |
| Inhibition of IgE-mediated secretion from human basophils with a highly selective Bruton's tyrosine kinase, Btk, inhibitor. | International immunopharmacology 20110401 |
| The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. | Arthritis research & therapy 20110101 |
| More than just B-cell inhibition. | Arthritis research & therapy 20110101 |
| Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase. | ChemMedChem 20070101 |